Buy Crypto Markets Spot FuturesGOLD Earn Event Center

BALLERUP, Denmark–(BUSINESS WIRE)–In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, andBALLERUP, Denmark–(BUSINESS WIRE)–In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, and

LEO Pharma Delivers 10% Revenue Growth in 2025 and More Than Doubles Adjusted EBITDA Margin

Author: AI Journal

Source: AI Journal

2026/02/18 16:15

5 min read

U$0.000961+3.33%

FREE$0.00005812-0.51%

FLOW$0.03488-1.38%

For feedback or concerns regarding this content, please contact us at [email protected]

BALLERUP, Denmark–(BUSINESS WIRE)–In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, and achieved a significant improvement in profitability, returning to positive net profit and free cash flow. The portfolio was strengthened by the launch of Anzupgo^® in 10 additional markets, including the U.S., as well as the addition of Spevigo^®. The pipeline was advanced through new late‑stage programs and strategic partnerships aimed at accelerating innovation. For 2026, revenue growth is expected to be 8-11% (CER), supporting further improvement in the adjusted EBITDA margin to 16-19%, alongside increased investments in innovation and LEO Pharma’s global platform.

Financial highlights

LEO Pharma’s revenue increased by 10% at constant exchange rates (CER) and by 8% in DKK to 13,499 million. Revenue growth was led by North America (+35% at CER), with Rest of World (+9% at CER) and Europe (+3% at CER) also contributing to the overall growth.
Revenue from the Dermatology portfolio grew by 12% (CER), driven by the Strategic brands Adtralza^®/Adbry^®, Anzupgo^®, and Spevigo^®, which combined had a revenue increase of 48% (CER), in addition to growth of 2% (CER) for the Established brands. Sales in the Critical Care portfolio declined by 1% (CER), affected by a reversal of sales discounts in the same period last year.
Operating profit improved sharply, with adjusted EBITDA reaching DKK 2,107 million in 2025, reflecting a margin of 16% (2024: 7%), excluding the STAT6 partnership upfront payment from Gilead Sciences received in January 2025 and other non-recurring items. The improvement in adjusted EBITDA was driven by sales growth and reduced operating expenses.
Net profit for 2025 was DKK 2,489 million (2024: negative DKK 1,776 million), including non-recurring items.
Free cash flow was DKK 1,875 million for 2025 (2024: negative DKK 52 million), and net interest-bearing debt was reduced to DKK 9,347 million (2024: DKK 11,115 million). Excluding M&A, free cash flow was DKK 940 million.

Innovation highlights

Anzupgo^® (delgocitinib) cream was launched in the U.S. in September as the first and only topical pan‑JAK inhibitor for chronic hand eczema, supported by a more than 50% increase in LEO Pharma’s U.S. sales force following FDA approval in July 2025.
Spevigo^® (spesolimab), an IL-36RA biologic for generalized pustular psoriasis, joined LEO Pharma’s portfolio on 30 September as its third global, first-in-class brand following a development and commercialization license secured from Boehringer Ingelheim.
In 2025, LEO Pharma entered several strategic partnerships to advance innovation, including an agreement with Gilead Sciences for the pre-clinical STAT6 program.
The pipeline was expanded with new late stage trials of Anzupgo^® (delgocitinib cream) in adults with palmoplantar pustulosis and lichen sclerosus, as well as the addition of an ongoing Phase 3 trial of Spevigo^® (spesolimab) in pyoderma gangrenosum.

2026 Outlook

For 2026, group revenue growth is expected at 8-11% (CER) driven by Anzupgo^® and Spevigo^®. The adjusted EBITDA margin is expected to improve to 16-19%, led by gross margin expansion, offset by higher commercial investments and R&D.

“2025 was another year of strong progress for LEO Pharma and a landmark year in our strategic transformation. We expanded our portfolio, delivered strong growth with significantly improved profitability, and formed new partnerships to accelerate innovation. With the ongoing launch of Anzupgo^® and the addition of Spevigo^®, we enter 2026 with strong momentum, committed to making a fundamental difference for patients by further unlocking the potential of our global platform.”
CEO Christophe Bourdon.

FY 2025 Financial overview

(DKK million)	FY 2025	FY 2024	Growth
Revenue	13,499	12,453	8%
Revenue growth at CER	10%	11%	N.m.
Adjusted EBITDA	2,107	895	135%
Adjusted EBITDA margin	16%	7%	N.m.
Net profit/(loss) for the period	2,489	(1,777)	N.m.

About LEO Pharma

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. Together, we reach far beyond the skin. For more information, visit www.leo-pharma.com

Financial highlights and key figures

(DKK million)	FY 2025	FY 2024

Income statement
Revenue	13,499	12,453
Of which dermatology revenue	10,991	10,008
Gross profit	8,240	7,518
Adjusted EBITDA ¹	2,107	895
Non-recurring items ¹	1,644	(295)
EBITDA ¹	3,751	600
Operating profit/(loss) (EBIT)	2,279	(1,143)
Net financials	(566)	(814)
Profit/(loss) before tax	1,713	(1,957)
Net profit/(loss) for the period	2,489	(1,776)

Balance sheet
Assets	20,445	20,151
Equity	5,262	2,704
Net working capital ²	3,991	3,833
Net interest-bearing debt (NIBD) ³	9,358	11,115
Invested capital ⁴	14,380	13,637

Cash flow
Cash flow from operating activities	1,255	265
Cash flow from investing activities	620	(317)
Free cash flow	1,875	(52)

Key ratios (%)
Revenue growth	8%	9%
Revenue growth at CER ¹	10%	10%
Dermatology revenue growth at CER	12%	12%
Gross margin	61%	60%
OPEX ratio	57%	70%
Adjusted EBITDA margin ¹	16%	7%
EBITDA margin ¹	28%	5%
EBIT margin	17%	(9)%
Effective tax rate	(45%)	9%
NIBD/Adjusted EBITDA (LTM) ⁵	4.4	12.4

People
Average number of full-time employees (FTE)	4,104	4,184

¹	See Note 2 Non-IFRS measures.
²	Net working capital comprises Inventories, Trade receivables and Other receivables less Trade payables and Other payables.
³	The net interest-bearing debt (NIBD) is the interest-bearing liabilities less cash and cash equivalents.
⁴	Invested capital is calculated as the sum of non-current assets, net working capital and tax receivables less deferred tax liabilities and other non-interest-bearing liabilities.
⁵	Adjusted EBITDA (LTM) is the adjusted EBITDA in the last 12 months.

Contacts

For further information please contact:

Investor Relations:
Christian Boas Ryom, telephone +45 4494 5888

Media:
Jeppe Ilkjær, telephone +45 3050 2014

Market Opportunity

Union Price(U)

$0.000961

$0.000961$0.000961

+2.45%

USD

Union (U) Live Price Chart

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.